192 related articles for article (PubMed ID: 19184600)
1. HLA ligand profiles of primary renal cell carcinoma maintained in metastases.
Stickel JS; Weinzierl AO; Hillen N; Drews O; Schuler MM; Hennenlotter J; Wernet D; Müller CA; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2009 Sep; 58(9):1407-17. PubMed ID: 19184600
[TBL] [Abstract][Full Text] [Related]
2. Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy.
Krüger T; Schoor O; Lemmel C; Kraemer B; Reichle C; Dengjel J; Weinschenk T; Müller M; Hennenlotter J; Stenzl A; Rammensee HG; Stevanović S
Cancer Immunol Immunother; 2005 Sep; 54(9):826-36. PubMed ID: 15627209
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells.
Seliger B; Dressler SP; Massa C; Recktenwald CV; Altenberend F; Bukur J; Marincola FM; Wang E; Stevanovic S; Lichtenfels R
Proteomics; 2011 Jun; 11(12):2528-41. PubMed ID: 21595034
[TBL] [Abstract][Full Text] [Related]
4. Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells.
Khan MI; Czarnecka AM; Lewicki S; Helbrecht I; Brodaczewska K; Koch I; Zdanowski R; Król M; Szczylik C
PLoS One; 2016; 11(11):e0165718. PubMed ID: 27812180
[TBL] [Abstract][Full Text] [Related]
5. Expression and regulation of non-classical HLA-G in renal cell carcinoma.
Dunker K; Schlaf G; Bukur J; Altermann WW; Handke D; Seliger B
Tissue Antigens; 2008 Aug; 72(2):137-48. PubMed ID: 18721274
[TBL] [Abstract][Full Text] [Related]
6. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
8. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
9. Quantification of HLA class I molecules on renal cell carcinoma using Edman degradation.
Stickel JS; Stickel N; Hennenlotter J; Klingel K; Stenzl A; Rammensee HG; Stevanović S
BMC Urol; 2011 Jan; 11():1. PubMed ID: 21251276
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis.
Buchner A; Castro M; Hennig A; Popp T; Assmann G; Stief CG; Zimmermann W
Urology; 2010 Aug; 76(2):507.e6-11. PubMed ID: 20538322
[TBL] [Abstract][Full Text] [Related]
11. Are primary renal cell carcinoma and metastases of renal cell carcinoma the same cancer?
Semeniuk-Wojtaś A; Stec R; Szczylik C
Urol Oncol; 2016 May; 34(5):215-20. PubMed ID: 26850779
[TBL] [Abstract][Full Text] [Related]
12. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-200b is downregulated and suppresses metastasis by targeting LAMA4 in renal cell carcinoma.
Li Y; Guan B; Liu J; Zhang Z; He S; Zhan Y; Su B; Han H; Zhang X; Wang B; Li X; Zhou L; Zhao W
EBioMedicine; 2019 Jun; 44():439-451. PubMed ID: 31130475
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.
Karim S; Al-Maghrabi JA; Farsi HM; Al-Sayyad AJ; Schulten HJ; Buhmeida A; Mirza Z; Al-Boogmi AA; Ashgan FT; Shabaad MM; NourEldin HF; Al-Ghamdi KB; Abuzenadah A; Chaudhary AG; Al-Qahtani MH
BMC Cancer; 2016 Sep; 16(Suppl 2):741. PubMed ID: 27766950
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma?
Atkins D; Ferrone S; Schmahl GE; Störkel S; Seliger B
J Urol; 2004 Feb; 171(2 Pt 1):885-9. PubMed ID: 14713847
[TBL] [Abstract][Full Text] [Related]
16. High expression of the long non-coding RNA HEIRCC promotes Renal Cell Carcinoma metastasis by inducing epithelial-mesenchymal transition.
Xiong J; Liu Y; Luo S; Jiang L; Zeng Y; Chen Z; Shi X; Lv B; Tang W
Oncotarget; 2017 Jan; 8(4):6555-6563. PubMed ID: 28030807
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
18. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
19. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance.
Masui O; White NM; DeSouza LV; Krakovska O; Matta A; Metias S; Khalil B; Romaschin AD; Honey RJ; Stewart R; Pace K; Bjarnason GA; Siu KW; Yousef GM
Mol Cell Proteomics; 2013 Jan; 12(1):132-44. PubMed ID: 23082029
[TBL] [Abstract][Full Text] [Related]
20. Gene signatures of progression and metastasis in renal cell cancer.
Jones J; Otu H; Spentzos D; Kolia S; Inan M; Beecken WD; Fellbaum C; Gu X; Joseph M; Pantuck AJ; Jonas D; Libermann TA
Clin Cancer Res; 2005 Aug; 11(16):5730-9. PubMed ID: 16115910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]